GF
NKTR icon

Gabelli Funds’s Nektar Therapeutics NKTR Stock Holding History

Gabelli Funds’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$367K Buy
+5,250
New +$384K ﹤0.01% 1109
2018
Q4 		– Sell
-233
Closed -$213K – 1153
2018
Q3 		$213K Buy
+233
New +$199K ﹤0.01% 1101

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gabelli Funds's NKTR Position: Q2 2026 in Review

Gabelli Funds opened a new position in Nektar Therapeutics (NKTR) in Q2 2026: 5,250 shares worth $367K. The stake represents ﹤0.01% of the portfolio and ranks #1109 among its holdings. This is a return to the name: Gabelli Funds previously reported a position in NKTR as recently as Q3 2018.

Gabelli Funds first reported a position in NKTR in Q3 2018 and has held it in 2 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Gabelli Funds held 5,250 shares of Nektar Therapeutics worth $367K as of Q2 2026.
  • Nektar Therapeutics was a new Gabelli Funds position in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Gabelli Funds's portfolio in Q2 2026, its #1109 holding.
  • Gabelli Funds first reported a position in Nektar Therapeutics in Q3 2018 and has held it in 2 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Gabelli Funds's 13F filing for Q2 2026, filed 12 Aug 2026.